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Growth hormone (GH) deﬁciency is related to an increased fracture risk although it is not clear if this is due to compromised
bone quality or a small bone size. We investigated the relationship between bone macrostructure, microarchitecture and mech-
anical properties in a GH-deﬁcient (GHD) mouse model undergoing GH treatment commencing at an early (prepubertal) or late
(postpubertal) time point. Microcomputed tomography images of the femur and L4 vertebra were obtained to quantify macro-
structure and vertebral trabecular microarchitecture, and mechanical properties were determined using ﬁnite element analyses.
In the GHD animals, bone macrostructure was 25 to 43% smaller as compared to the GH-suﬃcient (GHS) controls (P<0.001).
GHD animals had 20% and 19% reductions in bone volume ratio (BV/TV) and trabecular thickness (Tb.Th), respectively. Whole
bone mechanical properties of the GHD mice were lower at the femur and vertebra (67% and 45% resp.) than the GHS controls
(P<0.001).BothearlyandlateGHtreatmentpartiallyrecoveredthebonemacrostructure(15to32%smallerthanGHScontrols)
and the whole bone mechanical properties (24 to 43% larger than GHD animals) although there remained a sustained 27–52%
net deﬁcit compared to normal mice (P<0.05). Importantly, early treatment with GH led to a recovery of BV/TV and Tb.Th with
a concomitant improvement of trabecular mechanical properties. Therefore, the results suggest that GH treatment should start
early, and that measurements of microarchitecture should be considered in the management of GHD.
1.Introduction
Growth hormone (GH) plays an important role in the
growthofbone,andalackofGHduringdevelopmentresults
in a delayed bone age and reduced bone mineral density [1].
A GH deﬁciency in childhood is believed to cause an increas-
ed fracture risk and risk of osteoporosis later in life with GH
treatment potentially mitigating this risk [2, 3]. However,
the evidence to support this is controversial, and it has been
suggested that GH deﬁciency should no longer be listed as a
cause of osteoporosis in children [4].
Ah i g hp r e v a l e n c eo ff r a c t u r e sh a sb e e no b s e r v e di n
adults with hypopituitarism including GH deﬁciency with
onset in childhood or adulthood [5–7], and these increased
fracture rates have been mainly attributed to a lack of GH
[5, 6]. Children, adolescents, and adults with childhood-
onset isolated GH deﬁciency had an increased fracture risk
[6, 8], while a separate study found a low prevalence of
fractures in this same population [7]. GH treatment has
been shown to have a protective eﬀect by reducing fracture
frequencyalthoughthe mechanismsbehind this arenot clear
[8, 9].2 International Journal of Endocrinology
Studies have demonstrated that bone mineral density is
r e d u c e dw i t hG Hd e ﬁ c i e n c ya n dt h a tG Ht r e a t m e n tn o r -
malizes BMD [10–12]. These studies have relied primarily
on two-dimensional measures of density, which are aﬀected
by bone size [13]. When size corrections or volumetric den-
sity measurements are used, most studies suggest that a GH
deﬁciency results in normal or near-normal BMD [12, 14,
15], while some report below normal values [16].
Parameters that quantify trabecular microarchitecture
have been shown to relate strongly to bone strength [17].
Transiliac bone biopsies reveal no histomorphometric dif-
ferences between the trabecular bone of GH-deﬁcient men
andcontrols[18],andGHtreatmentinthissamepopulation
showed no changes in trabecular structure [19, 20]. In
moderately GH-deﬁcient rats, trabecular microarchitecture
was signiﬁcantly compromised with a smaller number of
thinner trabeculae and a reduced connectivity density [21].
In a previous study assessing changes in trabecular microar-
chitecture during growth using in vivo microcomputed
tomography (μCT), we showed that GH-deﬁcient mice have
compromised vertebral trabecular microarchitecture. Treat-
ment commencing prepuberty rescued the quantity of trabe-
cular bone but not the structure, while treatment after
puberty had no detectable eﬀect. GH-deﬁcient mice had
an increased number of thin trabeculae compared to GH-
suﬃcientmice,andGHtreatmentresultedinatrendtowards
further increases in the number of trabeculae [22]. To ex-
pand on this work, in this study, we sought to determine the
eﬀects of this altered microarchitecture on bone mechanical
properties as well as incorporate measures of bone macro-
structure using high-resolution in vitro μCT.
Some investigators have studied the eﬀects of GH on
bone strength. Growth hormone was shown to increase bone
strength in both young and old GH-suﬃcient rats, and this
increase has been attributed almost solely to a larger bone
size [23, 24]. In a rat model of osteoporosis, GH treatment
was shown to reverse the loss of bone strength by increasing
the ultimate stress and Young’s modulus to normal levels
[25].GH-deﬁcientmiceandratshaveimpairedcorticalbone
strength which was attributed to a reduction in cortical di-
ameter, and in mice the loss of strength was proportional to
the degree of GH deﬁciency [21, 26].
It is unclear what role microarchitecture plays in bone
strengthwithGHdeﬁciency,particularlysincepreviouswork
indicates that increased fracture risk may simply be due to
a smaller bone size. The purpose of this study is to under-
stand the role of trabecular and cortical bone mechani-
cal properties and their relation to microarchitecture and
macrostructure in a GH-deﬁcient mouse model. Our pre-
vious in vivo study focused on temporal changes in microar-
chitecture with GH treatment at the fourth lumbar vertebra.
Hereweusehigh-resolutioninvitroμCTimagingatmultiple
skeletal sites to address the hypothesis that GH-deﬁcient
mice have compromised trabecular microarchitecture in
addition to small bone size that together lead to a reduction
in mechanical properties. We test the hypothesis that com-
mencement of GH treatment before puberty results in a re-
covery of mechanical properties that accompany the
microarchitectural changes in contrast to when treatment is
started after puberty.
2. Methods
2.1. Experimental Design. Ghrhr homozygous “little” (lit/lit)
micewithaC57Bl/6backgroundhaveimpairedGHsynthesis
and release although injection of exogenous GH can stim-
ulate growth [27]. Heterozygous (lit/+)m i c eh a v en o r m a l
GH synthesis and release and are comparable to wild-type
C57Bl/6 mice. Breeding pairs of homozygous males and het-
erozygous females were purchased from The Jackson Labo-
ratory (Bar Harbour, Maine, USA). This breeding arrange-
m e n tw a su s e da sf e m a l eh o m o z y g o u sm i c eh a v ei m p a i r e d
ﬁrst lactations and, therefore, may lose their ﬁrst litter [28].
Oﬀspring were weaned at 21 days old and assigned to one
of ﬁve experimental groups: GH-suﬃcient (lit/+) controls,
GH-deﬁcient (lit/lit) controls, early treatment (lit/lit), late
treatment (lit/lit), and saline injection control (lit/lit). A
limitation of this mouse model was the large amount of time
required to breed the animals in-house (>2 years), result-
ing in the necessity of using both sexes to obtain a suﬃcient
sample size forthe experiment. All experimental groups con-
sisted of ﬁve male and ﬁve female mice, with the exception of
the saline injection control group, which was composed of
three male and three female mice. All animals were housed
in groups of the same sex and allowed ad libitum access to
standard rodent chow and water.
Early treatment and late treatment groups received daily
subcutaneous injections of 25μg of mouse recombinant
growth hormone (Dr. A. F. Parlow, National Hormone and
Peptide Program). The use of daily injections attempts to
mimic the physiological release of GH, which occurs in a
pulsatile manner with the largest peak release of GH occur-
ring during sleep [29]. The dose (25μg per mouse per day)
was chosen as it is within the wide range of doses which
stimulated growth in mice and rats [23, 24, 30]. Although
r e c o m b i n a n th u m a nG Hi so f t e nu s e dt ot r e a tG Hd e ﬁ c i e n c y
in animal experiments, antibody production can limit the ef-
ﬁcacy of this treatment [31].
Growth hormone was prepared as detailed by Kristensen
et al. [22]. The early treatment group received daily subcu-
taneous (sc) injections of 25μgo fG Hf r o ma g e2 1d a y st o
60 days, while the late treatment group received sc injections
of 25μg of GH from age 35 days to 60 days. At the age of
21 days, mice have not yet started puberty, while the age
of 35 days corresponds approximately to the end of puber-
ty [32]. Daily sc injections were used instead of continuous
dosing with infusion pumps due to the small size of the
mice at the study onset. The GH-deﬁcient mice remained
below the minimum body weight recommended for pump
implantationuntiltheday45timepoint.Thesalineinjection
control mice received daily sc injections of saline from age
21 days to 60 days to determine if the stress of daily injec-
tions has an eﬀect on bone microarchitecture or bone mech-
anical properties. All procedures were reviewed and ap-
proved by the University of Calgary Health Sciences Ani-
mal Care Committee, and experiments were conducted inInternational Journal of Endocrinology 3
compliance with this approval. Animals were cared for as per
the guidelines of the Canadian Council on Animal Care.
2.2. Imaging. At 60 days of age, the mice were euthanized by
CO2 inhalation, and the fourth lumbar vertebra (L4) and left
femur were dissected free and all soft tissue removed. Tissue
was stored at −30◦C in saline-soaked gauze until ready for
use. High-resolution μCT images (μCT35, Scanco Medical
AG) of the entire L4 vertebra and femur were obtained with
an integration time of 800ms, and X-ray settings of 55kVp,
and 145μA. The L4 vertebrae were scanned resulting in an
isotropic voxel sizeof3.5μm,and the dataweresubsequently
binned to 14μm (Image Processing Language (IPL) v5.08b,
Scanco Medical AG). The femora were scanned with an
isotropic voxel size of 10μm .A l li m a g e sw e r eG a u s s i a n
ﬁltered (vertebra: sigma = 1.0, support = 1; femur: sigma
= 1.2, support = 2), and a ﬁxed threshold of 22.0% of the
maximal gray scale value was applied to extract the minera-
lized tissue. The bones were positioned so that the long axes
of the vertebral body and the femur were aligned with the z
axis (IPL v5.08b, Scanco Medical AG).
2.3. Bone Geometry and Trabecular Microarchitecture
2.3.1. Vertebra. To calculate the vertebral body height, the
number of slices containing vertebral body bone was count-
ed and multiplied by the slice thickness. The cross-sectional
area (CSA) was obtained by calculating the area within
a hand-drawn contour of the vertebral body on the slice
located midway through the body. To quantify the trabecular
microarchitecture, the trabecular region of the vertebral
body was extracted by hand-drawing contours on every
fourth slice in the trabecular region between the growth
plates and applying a semiautomated morphing algorithm
totheinterveningslices.Bonemicroarchitecturalparameters
were calculated: bone volume ratio (BV/TV), trabecular nu-
mber (Tb.N), trabecular thickness (Tb.Th), trabecular sepa-
ration (Tb.Sp), structure model index (SMI), and connectiv-
ity density (Conn.D) (IPL, v5.08b, Scanco Medical AG). The
trabecularbonetissuemineraldensity(TMD)wascalculated
by normalizing the mineral content (as determined by X-ray
attenuation) by the trabecular bone volume.
2.3.2. Femoral Diaphysis. To calculate the full femur length,
the number of slices containing bone was summed and
multiplied by the slice thickness. All femur analyses (except
full femur length) were performed at femur diaphysis only,
which is a region consisting primarily of cortical bone. This
is in contrast to the vertebra which is mainly composed of
trabecularbone.Thesetworegionswereselectedsothatboth
cortical bone and trabecular bone properties could be as-
sessed.
The remainder of the femur analyses required that a sec-
tion of the femoral shaft be extracted. In order to analyse
comparableregionsofeachbone,theshaftlengthwaschosen
based on the sample’s aspect ratio. Therefore, the length
of the shaft (L) was unique for each model and was set
based on an aspect ratio of 6.0 multiplied by the shaft dia-
meter. The shaft diameter was calculated for a section of the
femoral shaft with a length equal to half of the entire bone
length. Thus, the ﬁnal femoral shaft models were created by
extracting a section of the shaft of length L,c e n t e r e da b o u t
the shaft midpoint which was deﬁned as 53% of the fe-
mur length as measured from the proximal end [33]. The
average cortical thickness (Ct.Th) of the femoral shaft model
was calculated by direct methods [27] (IPL, v5.08b, Scanco
Medical AG).
2.4. Finite Element Analysis. The ﬁnite element (FE) method
is a computational approach used to model the mechanical
behavior of materials and can determine mechanical proper-
ties of bone [34, 35]. For this study, μCT images are used as
thebasis of the model, as eachvoxel in the imageis converted
into an element in the mesh using the voxel conversion ap-
proach [36, 37].
2.4.1. Vertebra. Two FE analyses were performed on each
vertebra: a uniaxial compression of the whole bone, as well
as the calculation of the full stiﬀness matrix for a subvolume
of vertebral body trabecular bone [34].
Vertebra Whole Bone. Homogeneous, linear ﬁnite element
models of the extracted mineralized phase of the vertically
aligned whole vertebra images were created. Plano-parallel
loading surfaces were generated by digitally inserting cylin-
drical endcaps onto the vertebral endplates (Figure 1(c)).
The diameter of the endcaps was selected to enclose the en-
tire endplate. The top endcaps were assigned a thickness of
0.42mm, while the bottom endcaps were 0.35mm thick.
Vertebralprocessesweretrimmedsothattheydidnotextend
beyond the vertebral endplates. The voxel conversion ap-
proach was used to transform each voxel in the image into
a hexahedral element in the FE model. A Young’s modulus
of 19GPa and a Poisson’s ratio of 0.3 were assigned to bone
[38], while the endcaps were assigned material properties
equivalent to bone cement (PMMA): Young’s modulus =
2.5GPa, Poisson’s ratio = 0.3 [39]. The nodes on the bottom
surface of the lower endcap were constrained in the Z
d i r e c t i o nb u tf r e et om o v ei nt h eX and Y directions. The
nodes on the top surface of the upper endcap were free to
move in the X and Y directions and a uniaxial displacement
(δ) equivalent to 1% strain was applied in the Z direction.
ThemodelsweresolvedusingcustomFEsoftware(FAIM
v4.0) on a desktop computer (Mac, OS X, Version 10.5.6; 2
× 2.8GHz Quad-Core Intel Xeon). The meshes generated
from the whole vertebra models contained an average of 2.6
million nodes and 2.1 million elements. The output of the
models was the reaction force (F) required to induce 1%
strain. The axial rigidity (AE) was calculated as
AE =
Fh
δ
,( 1 )
where A is the cross-sectional area of the vertebral body, E
is the apparent level Young’s modulus, and h is the vertebral
body height.
Vertebra Trabecular Subvolume. A cubic subvolume of tra-
becular bone (130 × 130 × 130 voxels) was extracted4 International Journal of Endocrinology
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Figure 1: Finite element models. (a) Femur, positioned with condyles down, loaded in pure bending to an angle of 0.01 radians. (b) Cubes
of trabecular bone extracted from the distal region of the L4 vertebral body. On the left, bone from the GH-suﬃcient mouse and, on the
right, bone from a GH-deﬁcient mouse are pictured, each with the median apparent modulus in their respective groups. (c) Vertebrae with
endcaps digitally encasing the vertebral body endplates. Vertebrae were loaded in compression to 1% strain.
from the images with an isotropic voxel size of 3.5μm
(Figure 1(b)), and mineralized bone was identiﬁed as des-
cribed previously. The voxel conversion approach was ap-
plied, and three uniaxial strain compression and three uni-
axial shear strain tests were performed. The models were
solved using IPL (v5.11/FE-V01.15, Scanco Medical AG).
Themeshesgeneratedfromthetrabecularsubvolumeimages
containedanaverageof572,335nodesand471,255elements.
The stiﬀness matrix in the orthotropic principal coordinate
system was calculated [34], and the apparent Young’s modu-
lus in the ﬁrst principal direction was obtained.
2.4.2. Femoral Diaphysis. A homogeneous, linear ﬁnite ele-
ment analysis was performed to determine the ﬂexural rigid-
ity of the femoral diaphysis. As the ﬁnite element results are
calculated with the use of beam theory, and because mech-
anical properties calculated from beam theory are highly
dependent on the sample’s aspect ratio [33], this parameter
was held constant for all models. Therefore, the shaft length
was selected for each model based on an aspect ratio of 6.0,
as described previously (Section 2.3.2). The voxel conversion
approach was used to convert the femoral diaphysis image
into a FE model. A Young’s modulus of 19GPa and a Pois-
son’s ratio of 0.3 were assigned to all bone elements [38]. The
models were loaded in pure bending to an angle of 0.01 radi-
ans, and this load was applied with the femoral condyles fac-
ing downwards, which is a position consistent with that used
for mechanical testing (Figure 1(a)). The models were solved
using custom FE software (FAIM v4.0) on a desktop com-
puter (Mac, OS X, Version 10.5.6; 2 × 2.8GHz Quad-Core
Intel Xeon). The meshes generated for ﬁnite element analysis
resulted in an average of 5.3 million nodes and 4.8 million
elements for the full femur models. The ﬂexural rigidity (EI)
was calculated based on the moment (M)r e q u i r e dt ob e n d
the model to an angle of 0.01 radians (θ) and the length of
the femoral shaft (L)
EI =
ML
θ
. (2)
2.5. Statistics. Statistical signiﬁcance of the parameters was
tested by an analysis of variance (ANOVA). Where between-
subjects signiﬁcance was observed, a post hoc Tukey’s test
was used to determine diﬀerences between group means. All
statistical tests were performed with PASW Statistics version
17.0 (SPSS Inc, Chicago, USA). Diﬀerences were considered
statistically signiﬁcant with P<0.05 for all tests.
3. Results
There were no signiﬁcant diﬀerences between the GH-de-
ﬁcient and saline injection control mice for any parameter,
supporting the assumption that any stress due to daily injec-
tions did not have a detectable eﬀect on bone size, micro-
architecture, or mechanical properties.
3.1. TMD and Bone Macrostructure. All tissue mineral
density (TMD) and bone macrostructure results are listed
in Table 1, and the macrostructure results are displayed in
Figure 2. There were no detected diﬀerences in TMD be-
tween any of the groups. The GH-deﬁcient mice had a sig-
niﬁcantly smaller vertebral body height, vertebral body CSA,International Journal of Endocrinology 5
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Figure 2: Bone macrostructural results. From top to bottom, the rows display the whole femur, the femur cross-section (CSA), the whole
vertebra, and cubes of vertebral trabecular bone. For the whole femur, the animal with the median femoral length in each group is displayed,
and this same animal’s femur cross-section (at the shaft midpoint) is shown in the second row. For the whole vertebra, the mouse with the
median vertebral body height in each group is shown, and the animal with the median BV/TV in each group is depicted in the bottom row.
GH suﬃcient (GHS), GH deﬁcient (GHD), early treatment (early; daily GH injections from age 21 to 60 days), late treatment (late; daily
GH injections from age 35 to 60 days), and saline control (Saline; daily saline injections from age 21 to 60 days).
femoral length, femoral cortical thickness, and femoral CSA
than the GH-suﬃcient mice (25% to 43% smaller than GHS,
P<0.001). Growth hormone treatment was associated with
increases in these dimensions so that they were larger than
the GH-deﬁcient mice regardless of the age of onset of treat-
ment (10% to 23% larger than GHD, P<0.003). However,
all of these morphological parameters remained smaller in
both treatment groups compared to the GH-suﬃcient mice
(15% to 32% smaller than GHS, P<0.001), and thus GH
treatment only resulted in the partial rescue of bone macro-
structure. The only morphological parameter that showed
an eﬀect of early treatment was femur length, where a sig-
niﬁcantly longer bone length was observed with early GH
treatment as compared to late treatment (3% longer than
Late, P = 0.041). The femoral medullary CSA was signiﬁ-
cantly smaller in the GH-deﬁcient, early treatment, and late
treatment mice as compared to the GH-suﬃcient mice (29
to 39% smaller than GHS, P<0.001). There was a trend
towards an increase in medullary CSA with GH treatment
that was signiﬁcant for the late treatment group only (11 to
16% larger than GHD, P = 0.023).
3.2. Vertebral Microarchitecture. All vertebral microarchitec-
ture results are displayed in Table 2,a n dac u b eo fv e r t e b r a l
trabecular bone is displayed for the animal with the median
BV/TV in each group in Figure 2. The trabecular bone
volume ratio was signiﬁcantly smaller in the GH-deﬁcient L4
vertebrae as compared to the GH-suﬃcient vertebrae (20%
smaller than GHS, P = 0.031). Growth hormone treatment
was associated with an increase in the bone volume ratio
(BV/TV) in both the early and late treatment mice (14 to
25%largerthanGHD);however,thisincreasewassigniﬁcant
only between the early treatment and GH-deﬁcient mice
(P = 0.039),withnosigniﬁcantdiﬀerencesbetweentheearly
treatment and GH-suﬃcient mice. There were no signiﬁcant
diﬀerences in BV/TV between the late treatment and GH-
suﬃcient or GH-deﬁcient mice, indicating a partial recovery.
These same trends were observed for SMI, with a more rod-
like structure in the GH-deﬁcient mice compared to the GH
suﬃcientmice(68%largerthanGHS,P = 0.002).Arecovery
of SMI was observed in the early treatment group with a lack
of a signiﬁcant diﬀerence from the GH-suﬃcient mice but a
signiﬁcantly smaller SMI than the GH-deﬁcient mice (32%
smaller than GHD, P = 0.021). Again, a partial recovery was
evident in the late treatment group as no signiﬁcant diﬀer-
ences existed between this group and the GH-suﬃcient or
GH deﬁcient groups.
The GH-deﬁcient, early treatment, and late treatment
groups had signiﬁcantly thinner trabeculae than the GH suf-
ﬁcient groups (8 to 19% smaller than GHS, P<0.05). Early
treatment led to some recovery of Tb.Th as this parameter
was signiﬁcantly larger in the early treatment mice than the
GH-deﬁcient mice (14% larger than GHD, P = 0.001).
For Tb.N, Tb.Sp, and Conn.D, there were no detected
diﬀerences among any of the groups.
3.3. Mechanical Properties. The results for the mechanical
properties are displayed in Table 3. The GH-deﬁcient, early
treatment, and late treatment animals all have signiﬁcantly
less vertebral axial rigidity than the GH-suﬃcient animals
(27 to 45% smaller than GHS, P<0.001). However, GH
treatment resulted in partial recovery of this parameter as6 International Journal of Endocrinology
Table 1: Vertebral and femoral tissue mineral density (TMD) and bone macrostructure including cross-sectional area (CSA) and cortical
thickness (Ct.Th) in GH-suﬃcient (GHS), GH-deﬁcient (GHD), early treatment (early; daily GH injections from age 21 to 60 days), late
treatment (late; daily GH injections from age 35 to 60 days), and saline control (saline; daily saline injections from age 21 to 60 days). Mean
and standard errors are reported, and the coeﬃcient of variation (CV%). ∗P ≤ 0.05, ∗∗P ≤ 0.001 versus GHS, +P ≤ 0.05, ++P ≤ 0.001 versus
GHD, #P ≤ 0.05 versus early.
(a)
Group Vertebra body height (mm) Vertebra Body CSA (mm2) Vertebra TMD (mgHA/ccm)
GHS 3.19 ±0.040 1.82 ±0.030 829.8 ±10.1
GHD 2.28 ±0.041∗∗ 1.17 ±0.016∗∗ 819.5 ±9.0
Early 2.72 ±0.026∗∗++ 1.39 ±0.021∗∗++ 840.0 ±3.0
Late 2.69 ±0.042∗∗++ 1.43 ±0.043∗∗++ 821.0 ±6.9
Saline 2.26 ±0.063 1.18 ±0.036 832.7 ±5.8
CV% 4.9% 6.2% 2.6%
(b)
Group Femur length
(mm)
Femur CSA
(mm2)
Medullary CSA
(mm2)
Femur Ct.Th
(mm)
Femur TMD
(mgHA/ccm)
GHS 14.97 ±0.10 2.092 ±0.063 1.111 ±0.035 0.224 ±0.005 897.9 ±16.8
GHD 11.29 ±0.07∗∗ 1.190 ±0.020∗∗ 0.679 ±0.015∗∗ 0.150 ±0.002∗∗ 888.3 ±12.8
Early 12.72 ±0.08∗∗++ 1.421 ±0.030∗∗+ 0.752 ±0.017∗∗ 0.184 ±0.004∗∗++ 909.9 ±5.6
Late 12.37 ±0.08∗∗++# 1.429 ±0.046∗∗+ 0.786 ±0.024∗∗+ 0.176 ±0.005∗∗++ 905.9 ±6.3
Saline 11.32 ±0.04 1.218 ±0.039 0.702 ±0.029 0.150 ±0.004 898.8 ±5.9
CV% 1.8% 7.9% 8.8% 6.4% 3.3%
Table 2:Vertebraltrabecularmicroarchitecturalparametersincludingbonevolumeratio(BV/TV),connectivitydensity(Conn.D),structure
model index (SMI), trabecular number (Tb.N), trabecular separation (Tb.Sp), and trabecular thickness (Tb.Th) in GH-suﬃcient (GHS),
GH deﬁcient (GHD), early treatment (early; daily GH injections from age 21 to 60 days), late treatment (late; daily GH injections from age
35 to 60 days), and saline control (saline; daily saline injections from age 21 to 60 days). Mean and standard errors are reported, and the
coeﬃcient of varation (CV%). ∗P ≤ 0.05, ∗∗P ≤ 0.001 versus GHS, +P ≤ 0.05, ++P ≤ 0.001 versus GHD.
Group BV/TV (%) Conn.D
(1/mm3) SMI Tb.N
(1/mm)
Tb.Sp
(mm)
Th.Th
(mm)
GHS 25.29 ±1.05 363.8 ±22.30 .79 ±0.08 5.53 ±0.16 0.167 ±0.006 0.0512 ±0.0010
GHD 20.12 ±1.38∗ 358.7 ±40.11 .33 ±0.11∗ 5.84 ±0.21 0.160 ±0.007 0.0416 ±0.0009∗∗
Early 25.14 ±1.24+ 358.2 ±21.60 .91 ±0.10+ 6.12 ±0.16 0.147 ±0.005 0.0473 ±0.0008∗++
Late 22.95 ±0.99 350.7 ±20.51 .09 ±0.09 6.05 ±0.19 0.151 ±0.005 0.0452 ±0.0009∗∗
Saline 21.93 ±1.76 308.9 ±22.71 .23 ±0.11 6.10 ±0.26 0.150 ±0.007 0.0429 ±0.0015
CV% 16.7% 22.1% 27.7% 9.8% 6.7% 11.7%
Table 3: Mechanical properties in GH-suﬃcient (GHS), GH-deﬁcient (GHD), early treatment (early; daily GH injections from age 21 to
60 days), late treatment (late; daily GH injections from age 35 to 60 days), and saline control (saline; daily saline injections from age 21 to
60 days). Mean and standard errors are reported, and the coeﬃcient of varation (CV%). ∗P ≤ 0.05, ∗∗P ≤ 0.001 versus GHS, +P ≤ 0.05,
++P ≤ 0.001 versus GHD.
Group Femur ﬂexural rigidity
(N·mm2)
Vertebra axial rigidity
(N)
Vertebra trabecular apparent E
(MPa)
GHS 3021.2 ±156.6 7856.1 ±289.2 2463.5 ± 209.8
GHD 1006.9 ±32.3∗∗ 4321.9 ±167.8∗∗ 1545.4 ± 185.3∗
Early 1432.5 ±67.4∗∗+ 5757.7 ±183.9∗∗++ 2409.0 ± 210.5+
Late 1439.1 ±105.5∗∗+ 5373.7 ±239.2∗∗+ 1889.6 ± 116.3
Saline 1037.2 ±67.4 4348.8 ±208.0 1669.2 ± 286.1
CV% 16.1% 12.0% 30.8%International Journal of Endocrinology 7
both the early and late treatment mice have a larger axial
rigidity than the GH-deﬁcient mice (24 to 33% larger than
GHD, P<0.05).
Similar to the vertebrae, the femoral diaphyseal ﬂexural
rigidity was signiﬁcantly greater in the GH-suﬃcient group
as compared to the GH-deﬁcient, early treatment, and late
treatment groups (52 to 67% smaller than GHS, P<0.001).
Both early and late treatment resulted in partial recovery (42
to 43% larger than GHD, P<0.05).
The apparent Young’s modulus, reﬂecting the vertebral
trabecular bone mechanical properties, was signiﬁcantly
smallerintheGH-deﬁcientascomparedtotheGH-suﬃcient
mice (37% smaller than GHS, P = 0.012). There was a re-
covery of this parameter with early growth hormone treat-
ment leading to a signiﬁcant diﬀerence from GH-deﬁcient
mice (56% larger than GHD, P = 0.02) and no detected
diﬀerence from GH-suﬃcient mice—the trabecular bone
mechanical properties appear to have been rescued. Late
treatment may have also resulted in partial recovery of the
trabecular bone mechanical properties, but not as clearly as
for early treatment due to the lack of detected diﬀerences
from either GH-deﬁcient or GH-suﬃcient groups.
4. Discussion
This study provided novel insight into the relationships
betweencorticalandtrabecularbonemacrostructure,micro-
architecture, and mechanics in a GH-deﬁcient model. It
demonstrated that GH deﬁciency results in a deterioration
of bone size, microarchitecture, and mechanical properties,
and that GH treatment partially restored the bone size,
regardless of when the treatment was started (early or late).
Early treatment fully restored some important aspects of the
vertebraltrabecularmicroarchitecture,whilepartialrecovery
was observed in other aspects. In addition, late treatment
resulted in a less complete recovery of the trabecular micro-
architecture. The macrostructure and microarchitectural
changes were related to bone mechanical properties at two
skeletal sites (L4 vertebra and femoral diaphysis). It was
found that although both early and late GH treatment
resulted in partial recovery of the mechanical properties,
the remaining deﬁcit could be explained by compromised
macrostructure and not microarchitecture because it was
shown that, at least in the early treatment group, trabecular
mechanical properties were fully recovered.
Others have shown that GH deﬁciency results in a small
bone size, and this is consistent with the results observed in
this study. The GH treatment did not result in the recovery
of normal bone size, and similar trends were observed in
human studies where GH-deﬁcient children were signiﬁ-
cantly shorter than normal after six years of treatment [10].
As response to GH treatment in GHD children and animals
dependsonGHdose[24,40],itispossiblethatthedosegiven
to the mice in this study was not large enough to result in
full catch-up growth. While this dose is consistent with doses
that were shown to induce bone and muscle growth in both
GH-suﬃcient and -deﬁcient rodents [23, 24, 30], most of
those studies used a dose scaled to body weight. Thus as the
animals grew and increased body mass, the amount of GH
administered was increased. Additionally, it has been shown
that,usingaﬁxeddose,thegrowthresponsebluntswithtime
[41]. In this study, a constant dose that was independent of
body mass was administered, which could limit the response
to GH treatment.
Since the postnatal period (1 to 23 days of age) is the
most rapid growth phase for long bones in the mouse [42],
it is likely that GH treatment would be more eﬀective in
restoring normal bone length if administered during this
phase.However,therearepracticalchallengesassociatedwith
treating mice before the age of weaning at 21 days. The
small size of the pups prevents infusion pump implantation,
and potential rejection of the pup by its mother prohibits
daily manual injection. Thus, it was not possible to treat
these mice before weaning. However, continuing treatment
past the day 60 endpoint may also have resulted in a more
complete recovery of bone dimensions, as the duration of
GH treatment can have an impact on the response to GH
therapy [11].
The macrostructural results for the femur suggest that
the early treatment mice are at a more mature stage of
bone development than the late treatment mice at the
study endpoint. Normal bone growth in C57Bl/6 mice
involves rapid periosteal expansion until 28 days of age,
when expansion slows [43]. Endosteal expansion reaches its
peak at 56 days of age and afterwards decreases, showing a
net resorption of endosteal bone before 56 days and a net
apposition after this point [43]. The medullary CSA was
larger in the late treatment group and there was a trend
towards increased cortical thickness in the early treatment
group. This indicates that the early treatment group was
likely in the period of endosteal apposition while the late
treatment group was still in the endosteal resorption phase
at 60 days of age, suggesting that the early treatment group is
at a more advanced stage of cortical bone development.
GH-deﬁcient mice exhibited a signiﬁcant deterioration
of their trabecular microarchitecture, while mice treated
before puberty exhibited recovery of many aspects. This is
consistentwithourpreviouslongitudinalstudyofthesesame
mice that was based on lower resolution in vivo imaging. In
that study, we found a signiﬁcantly larger number of tra-
beculae in GH-deﬁcient, early treatment, and late treatment
animals as compared to GH-suﬃcient animals, with a trend
towards further increases with GH treatment [22]. Although
not signiﬁcant, the data presented here indicates that there
is a trend towards an increased number of trabeculae in all
of the GH-deﬁcient groups, with more prominent increases
in the treatment groups. Combined with the increase in
trabecular thickness with treatment, these results suggest
that mice receiving GH treatment have normalized bone
volume ratio through both increased number and thickness
of trabeculae.
An interesting result is that while bone size was not
restored in the GH-treated mice, some aspects of the micro-
architecture were indeed rescued. Thus, decreases of whole
bone mechanical properties can be attributed to smaller
bones, but not to deﬁcits in the bone microarchitecture. If
this animal model reﬂects the clinical situation, these results
suggest that assessments of the eﬀectiveness of GH therapy8 International Journal of Endocrinology
must go beyond measuring bone size and density and should
include the eﬀect of GH on microarchitectural changes.
Withemergingtechnologies(e.g.,high-resolutionperipheral
quantitative computed tomography), this approach to clini-
cal assessment may become feasible in the near future.
There were no diﬀerences in tissue mineral density de-
tected between any of the groups, and this is in agreement
with the majority of human studies measuring volumetric
or size-adjusted BMD but diﬀers from GHD animal models
where decreased BMC and BMD were observed [44],
including our recent in vivo study [22]. It is probable that
the discrepancy is due to diﬀerences in image resolution
which inﬂuence partial volume eﬀects and TMD estimates.
Considering the limitations of TMD measurements with the
polychromatic X-ray source used in μCT, it may be necessary
in the future to use synchrotron μCT. Regardless, if there is
truly an eﬀect of GH treatment on TMD, the eﬀect is likely
small. The rationale for including the assessment of TMD in
this study was that it conﬁrms that the use of a homogeneous
tissue modulus in the ﬁnite element analysis is a reasonable
approach.
Al a c ko fg r o w t hh o r m o n el e dt oar e d u c t i o no ff e m o r a l
ﬂexural rigidity and vertebral axial rigidity, and partial
recovery of both of these parameters was evident with GH
treatment. These parameters are dependent on bone size
and therefore are aﬀe c t e db yt h er e d u c e db o n es i z ei n
GH-deﬁcient animals and partial size recovery with GH
therapy. Since the structure of trabecular bone plays a role in
mechanical behavior, the mechanics results for the vertebrae
are not simply a function of size, but of the structure of the
trabecular bone as well. The FE results for isolated trabecular
bone subvolumes indicated that the trabecular structure of
GH-deﬁcient animals was signiﬁcantly weaker, and that early
GH treatment restored the trabecular mechanical properties.
Therefore, this further supports the notion that the deﬁcits
in vertebral axial rigidity in early treatment animals are
likely caused by a smaller bone size, and not by a weakened
microarchitecture. Although early treatment does not fully
restore bone size, resulting in a net deﬁcit in the whole bone
mechanicalproperties,therecoveryoftrabecularmechanical
properties is likely valuable for reducing fracture risk in
the long term. In the late treatment mice, a similar pattern
was observed; however, the trabecular mechanical properties
were not completely rescued. Together these results conﬁrm
support for the previous ﬁnding that it is important for GH
treatment to be commenced early.
There were limitations in this study that deserve men-
tion. First, the ﬁnite element analyses did not incorporate
variations in tissue modulus and therefore only assessed the
contributionsofsizeandstructureonmechanicalproperties.
Nevertheless, it would have been diﬃcult to justify incorpo-
rating tissue mineral density due to the lack of signiﬁcant
diﬀerences found among groups. Second, in the small mouse
bones, it was challenging to extract trabecular subvolumes
with at least ﬁve trabeculae as suggested by Harrigan et al.
[45] for continuum assumptions. This was due to the small
size and irregular shape of the vertebral bodies in the mouse
and may be justiﬁcation to consider a larger animal model
in the future (e.g., rat). Finally, it should be noted that the
ﬁndings in this study using a mouse model are not directly
applicable to human patients, and further research is needed
to explore the importance of timing of GH treatment on
bone health in people. This research would be particularly
interesting to pursue using new clinical 3D technologies such
as high-resolution peripheral quantitative computed tomog-
raphy on patient cohorts to assess human bone microarchi-
tecture (rather than only bone mineral density by DXA).
In summary, GH deﬁciency resulted in reduced bone
macrostructure, a deteriorated trabecular microarchitecture,
and decreased bone mechanical properties as compared to
GH-suﬃcient controls. Treatment with sc GH was unable to
fully recover bone size although the trabecular mechanical
properties in the early treatment group were fully restored
despite the net reduction in whole bone strength. Therefore,
the beneﬁts of GH therapy on bone health may be under-
estimated when clinical assessments rely solely on measures
of bone size and density (i.e., DXA) because recovered
trabecular microarchitecture may go undetected.
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